Back to results
US 10,119,168 B2Granted
Methods for the treatment of kidney fibrosis
AssigneeThe Brigham and Women's Hospital, Inc.
InventorsVishal S. Vaidya, Florin Craciun, Amrendra K. Ajay
Life of this patent
Estimating the term…
Abstract
The technology described herein is directed to the diagnosis, prognosis, and treatment of kidney fibrosis, e.g., chronic kidney disease.
Claims12
A method of treatment for kidney fibrosis or chronic kidney disease comprising;
- selecting a subject determined to have
- i. an increased level of expression of at least one gene selected from the group consisting of:
- ADAM metallopeptidase with thrombospondin type 1 motif 16 (Adamts16);
- C-C motif chemokine ligand 2 (Ccl2);
- C-C motif chemokine ligand 6 (Ccl6);
- C-C motif chemokine ligand 15 (Ccl15);
- C-C motif chemokine ligand 9 (Ccl9);
- C-C motif chemokine receptor 2 (Ccr2);
- claudin 3 (Cldn3);
- Collagen type III alpha 1 chain (Col3a1);
- Collagen type VIII alpha 1 chain (Col8a1);
- caboxypeptidase N subunit 1 (Cpn1);
- Endothelin 1 (Edn1);
- adhesion G protein-coupled receptor E1 (Emr1);
- fibronectin 1 (Fn1);
- gamma-aminobutyric acid type A receptor pi subunit (Gabrp);
- histocompatibility 2, class II, locus Mb1 (H2-Dmb1);
- major histocompatibility complex, class II, DM beta (HLA-DMB);
- integrin subunit alpha M (Itgam);
- lipopolysaccharide binding protein (Lbp);
- lysozyme 2 (Lyz2);
- lysozyme (Lyz);
- matrix Gla protein (Mgp);
- matrix metallopeptidase 7 (Mmp7);
- mannose receptor C-type 1 (Mrc1);
- NFAT activating protein with ITAM motif 1 (Nfam1);
- neuropeptide Y receptor Y6 (Npy6r);
- podoplanin (Pdpn);
- phospholipase D family member 4 (Pld4);
- phospholipid transfer protein (Pltp);
- sodium voltage-gated channel, alpha subunit alpha (Scn7a);
- semaphorin 3D (Sema3d);
- serpin family E member 2 (Serpine2);
- SPARC related modular calcium binding 2 (Smoc2);
- stimulated by retinoic acid 6 (Stra6);
- synaptotagmin like 2 (Sytl2);
- tenascin C (Tnc);
- and TYRO protein tyrosine kinase binding protein (Tyrobp)
- as compared to a reference level, in a urine sample obtained from the subject;
- ii. normal levels of a) serum creatine orb) urinary albumin or protein;
- administering to the subject at least one of:
- a) a dialysis treatment;
- and
- b) at least one compound selected from the group consisting of:
- an ACE inhibitor;
- an angiotensin II receptor blocker (ARB);
- D vitamin supplementation;
- or an antagonist of the at least one selected gene.
45 more elements
A method of treatment for kidney fibrosis or chronic kidney disease comprising;
- selecting a subject determined to have
- i. an increased level of expression of SPARC related modular calcium binding 2 (Smoc2);
- as compared to a reference level, in a urine sample obtained from the subject;
- and
- ii. normal levels of a) serum creatine or b) urinary albumin or protein;
- administering to the subject
- at least one of
- a) a dialysis treatment;
- and
- b) at least one compound selected from the group consisting of:
- an ACE inhibitor;
- an angiotensin II receptor blocker (ARB);
- D vitamin supplementation;
- or an antagonist of Smoc2.
11 more elements
Dependencies are inferred from the claim text.